Skip to main content

Therapeutic approaches for RyR1-related myopathies

Master 2 - Team "Cellular Myology and Pathologies"

Internship

Objectives

The project aims at a better understanding of the mechanism of action of antioxidant treatment in RyR1-RD myopathies.

Abstract

RyR1-related disorders (RyR1-RD) represent the most common congenital myopathies, with a severity ranging from generalized muscle weakness to perinatal lethality, with a possible neurological involvement, and are due to mutations in the RYR1 gene encoding the main intracellular calcium channel of skeletal muscle also expressed in some neurons. Due to its large size, the huge number of mutations in the RYR1 gene and the restricted number of patients, therapeutic approaches are limited up to now to physical therapy. Our group has produced and characterized a mouse model (so called RyR1-Rec) in which a muscle specific reduction in the RyR1 expression induces the apparition of a progressive myopathy mimicking the patients' disease. In preliminary experiments, we tested an antioxidant as a potential therapy and observed a spectacular improvement of muscle strength in this mouse model. The project aims at a better understanding of the mechanism of action of the antioxidant in our model, in order to further identify more efficient therapeutic molecules that could be used as a treatment for RYR1-RD.

Methods

In vivo animal experimentation, primary muscle cell culture, immuno-fluorescence, western blot, immunoprecipitation , biochemical assays, functional assay (calcium imaging).

Reference

Tourel A, Reynaud-Dulaurier R, Brocard J, Fauré J, Marty I, Petiot A. RyR1 Is Involved in the Control of Myogenesis. Cells. 2025 Jan 21;14(3):158. doi: 10.3390/cells14030158

Beaufils M, Melka M, Brocard J, Benoit C, Debbah N, Mamchaoui K, Romero NB, Dalmas-Laurent AF, Quijano-Roy S, Fauré J, Rendu J, Marty I. Functional benefit of CRISPR-Cas9-induced allele deletion for RYR1 dominant mutation. Mol Ther Nucleic Acids. 2024 Jun 17;35(3):102259. doi: 10.1016/j.omtn.2024.102259

Pelletier L, Petiot A, Brocard J, Giannesini B, Giovannini D, Sanchez C, Travard L, Chivet M, Beaufils M, Kutchukian C, Bendahan D, Metzger D, Franzini Armstrong C, Romero NB, Rendu J, Jacquemond V, Fauré J, Marty I. In vivo RyR1 reduction in muscle triggers a core-like myopathy. Acta Neuropathol Commun. 2020 Nov 11;8(1):192. doi: 10.1186/s40478-020-01068-4

Requested domains of expertise

Interest in cell biology and in deciphering physio-pathological mechanisms

Contact

Anne Petiot, Inserm Researcher
Mail : anne.petiotatuniv-grenoble-alpes.fr
Phone : +33 (0)4 56 52 05 71

Download

M2 Internship Proposal 2025-26 APetiot (PDF, 105.51 KB)

Contacts

Pour les stages (master, licence, 3ème), envoyer directement un email au responsable de l'équipe que vous avez identifiée.

Pour une candidature spontanée pour un emploi, utilisez le formulaire de contact.

Submitted on February 8, 2024

Updated on June 23, 2025